Free Trial
NASDAQ:QNTM

Quantum Biopharma Q2 2025 Earnings Report

Quantum Biopharma logo
$3.64 -0.06 (-1.62%)
Closing price 04:00 PM Eastern
Extended Trading
$3.63 -0.01 (-0.27%)
As of 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Quantum Biopharma EPS Results

Actual EPS
-$3.23
Consensus EPS
-$0.17
Beat/Miss
Missed by -$3.06
One Year Ago EPS
N/A

Quantum Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.89 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quantum Biopharma Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Quantum Biopharma's next earnings date is estimated for Thursday, August 6, 2026, based on past reporting schedules.

Conference Call Resources

Quantum Biopharma Earnings Headlines

Elon Is Quietly Doubling Down on This Bizarre Asset
Yahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon Musk has been quietly doubling down on it, even attempting to deploy it during his time at DOGE before being shut down. Investing legend Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - has spent six years analyzing this sector he calls 'W.T.E.' He believes it could be 90 times bigger than AI and 1,900 times bigger than Bitcoin.tc pixel
See More Quantum Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email.

About Quantum Biopharma

Quantum Biopharma (NASDAQ:QNTM) is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

View Quantum Biopharma Profile